Effective, nonsensitizing vaccination with culture filtrate proteins against virulent Mycobacterium bovis infections in mice

Infection and Immunity

Volumn 66, Issue 10, 1998, Pages 5048-5051

  Bosio, Catharine M ^a,b   Orme, Ian M ^a  

^a Immunology and Pathology   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; BCG PASTEUR; BCG VACCINE; QUIL A; TUBERCULIN; UNCLASSIFIED DRUG;

AEROSOL; ANIMAL MODEL; ARTICLE; BACTERIAL VIRULENCE; BACTERIUM CULTURE; BCG VACCINATION; CONTROLLED STUDY; EXPERIMENTAL INFECTION; INFECTION RESISTANCE; MOUSE; MYCOBACTERIOSIS; MYCOBACTERIUM BOVIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONTENT; TUBERCULOSIS; VACCINATION;

EID: 0031660826     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.66.10.5048-5051.1998     Document Type: Article

References (30)

1. Alving, C. 1997. Immune reactions of lipids and lipid model membranes, p. 220-321, In M. Sela (ed.), The antigens, vol. IV. Academic Press. New York, N.Y.
2. Anacker, R. L., W. R. Barclay, W. Brehmer, C. L. Larson, and E. Ribi. 1967. Duration of immunity in mice vaccinated intravenously with oil treated cell walls of Mycobaterium bovis strain BCG. J. Immunol. 98:1265-1273.
3. Andersen, P. 1994. Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins. Infect. Immun. 62:2536-2544.
4. Baldwin, S. L., C. D'Souza, A. D. Roberts, R. P. Kelly, A. A. Frank, M. A. Lui, J. B. Ulmer, K. Huygen, D. M. McMurray, and I. M. Orme. 1998. Evaluation of new vaccines in the mouse and guinea pig model of tuberculosis. Infect. Immun. 66:2951-2959.
5. Bosio, C. M., and I. M. Orme. Unpublished data.
6. Buddle, B. M., G. W. DeLisle, A. Pfeffer, and F. E. Aldwell. 1995. Immunological responses and protection against Mycobacterium bovis in calves vaccinated with a low dose of BCG. Vaccine 13:1123-1130.
7. Buddle, B. M., D. Keen, A. Thomson, G. Jowett, R. McCarthy, J. Heslop, G. W. DeLisle, J. L. Stanford, and F. E. Aldwell. 1995. Protection of cattle from bovine tuberculosis by vaccination with BCG by the respiratory or subcutaneous route, but not by vaccination with killed Mycobacterium vaccae. Res. Vet. Sci. 59:10-16.
8. Cleland, J. L., C. R. Kensil, A. Lim, N. E. Jacobsen, L. Basa, M. Spellman, D. A. Wheeler, J. Y. Wu, and M. F. Powell. 1996. Isomerization and formulation stability of the vaccine adjuvant QS-21. J. Pharm. Sci. 85:22-28.
9. Cooper, A. M., D. K. Dalton, T. A. Stewart, J. P. Griffin. D. G. Russell, and I. M. Orme. 1993. Disseminated tuberculosis in inturferon gamma genedisrupted mice. J. Fxp. Med. 178:2243-2247.
10. Dalsgaard, K. 1978. A study of the isolation and characterization of the saponin Quil-A. Evaluation of its adjuvant activity, with special reference to the application in the vaccination of cattle against foot and mouth disease. Acta Vet. Scand. Suppl. 869:1. (Abstract.)
11. Firis, T., C. Costopoulos, A. J. Radford, A. Bacic, and P. R. Wood. 1991. Purification and characterization of major antigens from a Mycobacterium bovis culture filtrate. Infect. Immun. 59:800-807.
12. Harboe, M., H. G. Wiker, and S. Nagai. 1992. Protein antigens of mycobacteria studied by quantitative immunological techniques. Clin. Infect. Dis. 14:313-319.
13. Haslov, K., A. B. Andersen, and M. W. Benntzon. 1987. Biological activity in sensitized guinea pigs of MPB 70, a protein specific for some strains of Mycobacterium bovis BCG. Scand. J. Immunol. 26:445-454.
14. Huhbard, R. D., C. M. Flory, and F. M. Collins. 1992. Immunization of mice with mycobaeierial filtrate proteins, Clin. Exp. Immunol. 87:94-98.
15. Hussein, S., J. Curtis, H. Akuffo, and J. L. Turk. 1987. Dissociation between delayed-type hypersensiiivity and resistance to pathogenic mycobacteria demonstrated by T-cell clones. Infect. Immun. 55:564-567.
16. Johnson, C. J. 1997. Mycobacterium tuberculosis: age-old questions answered with modern technology. Ph.D. thesis. Colorado State University, Fort Collins.
17. Kensll, C. R. 1996. Saponins as vaccine adjuvants. Crit. Rev. Ther. Drug Currier Syst. 13:1-55.
18. Kensil, C. R., S. Solyysik, D. A. Wheeler, and J. Y. Wu. 1996. Structure/ function studies on QS-21, a unique immunological adjuvant from Quillaja saponaria. Exp. Med. Biol. 404:165-172.
19. Lindblad, E. B., M. J. Elhay, R. Silva, R. Appelberg, and P. Andersen. 1997. Adjuvant modulation of immune responses to tuberculosis subunit vaccines. Infect. Immun, 65:623-629.
20. Livingston, P. O., S. Alduri, F. Helling, T. J. Yao, C. R. Kensil, M. J. Newman, and D. Maricani. 1994. Phase I trial of immunological adjuvant OS-21 with GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma. Vaccine 12:1275-1280.
21. Mannhalter, J. W., H. O. Neychev, G. J. Zlabinger, R. Ahmad, and M. M. Eibl. 1985. Modulation of the human immune response by the nonionic and non-pyrogenic adjuvant aluminum hydroxide: effect on antigen uptake and antigen presentation. Clin. Exp. Immunol. 61:143-151.
22. Ordway, D. J., M. G. Sonnenberg, S. A. Donahue, J. T. Belisle, and I. M. Orme. 1995. Drug-resistant strains of Mycobacterium tuberculosis exhibit a range of virulence for mice. Infect. Immun. 63:741-743.
23. Orme, I. M. 1988. Induction of nonspecific acquired resistance and delayed-type hypersensiiivity, but not specific acquired resistance, in mice inoculated with killed mycobacterial vaccines. Infect. Immun. 56:3310-3312.
24. Orme, I. M., and F. M. Collins. 1994. Mouse model of tuberculosis, p. 113-134. In B. R. Bloom (ed.), Tuberculosis: pathogenesis, protection, and control. ASM Press, Washington, D.C.
25. Orme, I. M., and F. M. Collins. 1986. Aerogenic vaccination of mice with Mycobacterium bovis BCG. Tubercle 67:133-140.
26. Pal, P. G., and M. A. Horwitz. 1992. Immunization with extracellular proteins of Mycobacterium tuberculosis induces cell-mediated immune responses and substantial protective immunity in a guinea pig model of pulmonary tuberculosis. Infect. Immun. 60:4781-4792.
27. Powell, M. F., D. J. Eastman, A. Lim, C. Lucas, M. Peterson, J. Vennari, R. P. Weissberg, T. Wrin, C R. Kensil, and M. J. Newman. 1995. Effect of adjuvants on immunogenicity of MN recombinant glycoprotein 120 in guinea pigs. AIDS Res. Hum. Retroviruses 11:203-209.
28. Roberts, A. D., M. G. Sonnenberg, D. J. Ordway, S. K. Furney, P. J. Brennan, J. T. Belisle, and I. M. Orme. 1995. Characteristics of protective immunity engendered by vaccination of mice with purified culture filtrate protein antigens of Mycobacterium tuberculosis. Immunology 85:502-08.
29. Soltysik, S., j. Y. Wu, J. Recchia, D. A. Wheeler, M. J. Newman, R. T. Coughlln, and C. R. Kensil. 1995. Structure/function studies of QS-21 adjuvant: assessment of triperene aldehyde and glucuronic acid roles in adjuvant function, Vaccine 13:1403-1410.
30. Thoen, C. O., and J. H. Steele. 1995. Preface, p. iv. In C. O. Thoen and J. H. Stock (ed.), Mycobacterium bovis infection in animals and humans. Iowa State University Press, Ames.